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For few years now, the use of monoclonal antibodies
represents a significant progress in different therapeutic
applications. In addition to commercialization of new
products, important efforts in research and development
have been made to launch new therapeutic antibodies.
Many antibodies act through a mechanism of Anti-
body-dependant cell cytotoxicity (ADCC). National
Health Agencies recommend or require the use of biolo-
gical activity assays (potency) in order to characterize
those pharmaceutical products. The ADCC assay com-
bines the 3 following elements:
￿ T h ea n t i b o d yo fi n t e r e s tt h a ti ss p e c i f i ct oag i v e n
antigen;
￿ The targeted cells that express the antigen of interest
at their surface;
￿ The effector that can trigger the lysis the targeted
cell when the antibody is linked to the antigen.
As the usually met ADCC assays use Natural Killer
cells, isolated from healthy donors, as effectors they are
hardly reproducible (Table 1). Thus, those assays can
barely be validated when lots of pharmaceutical pro-
ducts are released. Furthermore, of the rare NK cell
lines established in culture don’te x p r e s st h eC D 1 6
receptor needed for the ADCC function.
In this context, the use of standardized effectors
should improve significantly the ADCC assays. Previous
work has highlighted that human lymphocytes, modified
to express the CD16 receptor, have acquired the ADCC
functions [1]. Thanks to our specific know-how, clones
of CD16+ lymphocytes have been produced on a large
scale (10
9 cellules). The results obtained have pointed
out that cells stored in liquid nitrogen and used as soon
as they were thawed, were usable for ADCC assays on a
reproducible basis (Figure 1). Thanks to that approach,
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Table 1 Advantages and drawbacks of ADCC effectors for the validation of a standardized ADCC assay
ADCC effector types Advantages Drawbacks
Primary NK or PBMC, isolated from
donors
Representative from the genetic diversity Not convenient for standardization
Requirement for donor genotyping
Requirement to evaluate several donors for accurate comparison
Exposure of operators to biohazard
Significant ressources required (budget and time) for cell
preparation
Modified NK cell lines Increased suitability for standardization The NK activity may interfere with the measurement of the
ADCC-related lysis
Absence of functionally qualified batches of cells
Absence of biosafety qualified batches of cells
To be handled as a GMO
CD16-transduced lymphocytes Increased suitability for standardization
Qualified batches available in a ready-to-
use format
Absence of NK activity-related background
To be handled as a GMO
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the present presentation: CD20 and Her2neu.
The produced effector cells constitute a relevant alter-
native to replace the use of NK cells when the standar-
dization of ADCC potency assay is needed.
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Figure 1 Characterization of ADCC function of CD16-transduced lymphocytes. Two models of antigen expressing cells were used to
establish the inter-assay precision of the ADCC measurement in a standard chromium-release assay. Briefly, the cells were
51Cr-labelled, washed,
incubated with the antibodies and the release of
51Cr in the supernatant was analyzed after 4h.
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